autologous anti-HPV-16 E6 T-cell receptor gene-engineered peripheral blood lymphocytes

{
  "id": "MLC-T-ONC-011458",
  "term": "autologous anti-HPV-16 E6 T-cell receptor gene-engineered peripheral blood lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "Human autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding a T-cell receptor (TCR) that is specifically directed against the viral oncoprotein human papillomavirus type 16 (HPV-16) E6, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous anti-HPV-16 E6 TCR gene-engineered PBLs bind to HPV-16 E6-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of HPV-16 E6-positive cancer cells. HPV-16 E6, a cell surface glycoprotein, is overexpressed by a variety of HPV-associated cancers and is absent from healthy human tissues.",
  "synonyms": [
    "autologous anti-HPV-16 E6 TCR gene-engineered PBLs",
    "autologous anti-HPV-16 E6 TCR gene-engineered peripheral blood lymphocytes"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-hpv-16-e6-t-cell-receptor-gene-engineered-peripheral-blood/"
}